Welcome to our dedicated page for Escalon Medical SEC filings (Ticker: ESMC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Escalon Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Escalon Medical's regulatory disclosures and financial reporting.
Escalon Medical Corp (ESMC) Schedule 13G/A filed by Charles C. Newton reports zero beneficial ownership of the issuer's common stock. The filing states the reporting person holds 0 shares, representing 0
Escalon Medical Corp. (ESMC) reported consolidated net revenue of $12,046,000 for year ended June 30, 2025, a 0.5% increase versus prior year. Cost of revenue totaled $6,535,000 or 54.3% of revenue, a 2.7 percentage-point improvement driven by a change in product mix. The company reported increased Trek sales offset by declines in Sonomed and AXIS revenues.
The company has an accumulated deficit of $68.4 million, 7,415,329 shares outstanding, and an OTCQB closing price of $0.37 as of September 26, 2025 (aggregate market value of non‑affiliate equity ~$386,652). Independent auditors and management disclosed substantial doubt about the company’s ability to continue as a going concern. A related‑party holder controls approximately 77.81% of voting power via Series A preferred stock, convertible into 4,300,000 common shares (≈36.7% on conversion). The filing highlights working capital deficiencies, supplier and customer concentration, and ongoing evaluation of new accounting standards.
FAQ
What is the current stock price of Escalon Medical (ESMC)?
